Zhihua Huang

Title: Zhihua Huang: Innovator in Cancer Treatment

Introduction

Zhihua Huang is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of cancer treatment through his innovative research and development of bispecific antigen binding proteins. With a total of 8 patents to his name, Huang's work is paving the way for new therapeutic approaches in oncology.

Latest Patents

Huang's latest patents include groundbreaking inventions such as "Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof." This invention provides bispecific antigen binding proteins (BSAPs) that specifically bind to CD3 and a tumor antigen, such as CD19. The applications of these BSAPs extend to the preparation of pharmaceutical compositions, methods of treating cancer, and kits comprising the BSAPs. Another notable patent is "Multispecific fab fusion proteins and use thereof," which introduces multispecific Fab fusion proteins (MSFP) that specifically bind to CD3 and EpCAM. This invention also outlines the uses of MSFPs for pharmaceutical compositions, cancer treatment methods, and related kits.

Career Highlights

Zhihua Huang has worked with notable companies in the biotechnology sector, including Generon (Shanghai) Corporation Ltd. and Itabmed (HK) Limited. His experience in these organizations has contributed to his expertise in developing innovative cancer therapies.

Collaborations

Huang has collaborated with several professionals in his field, including Xiaoqiang Yan and Yuliang Huang, who is a woman. These collaborations have further enhanced his research and development efforts in cancer treatment.

Conclusion

Zhihua Huang's contributions to cancer treatment through his innovative patents and collaborations highlight his role as a leading inventor in the biotechnology field. His work continues to inspire advancements in therapeutic approaches for cancer patients.